Home / News & Videos / News / Medical Research /

V-Smart Tech Could Be Answer to Brain Tumor Treatment

V-Smart Tech Could Be Answer to Brain Tumor Treatment

July 2, 2015

Medical Research, Nanotechnology, Press Releases

Lauren Sciences LLC, the private New York biotechnology company developing breakthrough V-Smart™ Nanomedicines for brain diseases, announced today the receipt of a grant from Voices Against Brain Cancer (VABC). The grant will support the development of a V-Smart™ drug delivery for glioblastoma multiforme (GBM), the most aggressive malignant primary brain tumor in humans.

The Lauren Sciences’ research team and laboratories are located at Ben-Gurion University of the Negev, where the V-Smart™ technology was invented before it was licensed to Lauren Sciences.

brain-april-2014“V-Smart™ for GBM, formulated with a potent anti-tumor agent, has promise as an effective new treatment for GBM patients,” said Irwin Hollander, Ph.D., vice president for research and development at Lauren Sciences. “Our goal for this new V-Smart™ drug is to stop progression of, or eradicate, GBM, unlike standard treatments that in the vast majority of patients merely delay disease progression.

“We anticipate future efficacy studies of V-Smart™ in GBM pre-clinical models and, thereafter, clinical studies in patients. Our goal is clinical validation and approval of this V-Smart™ for GBM.”

V-Smart™ for GBM will target and deliver a known chemotherapeutic that has proven potential to treat the brain tumor, but does not cross the blood-brain barrier (BBB) on its own. V-Smart™ Nanomedicines are designed to target and deliver therapeutics across the BBB and into selective brain cells both non-invasively and effectively.

“We thank Voices Against Brain Cancer for their award,” said Susan Rosenbaum, J.D., founder, chairman and chief executive officer of Lauren Sciences. “VABC’s grant is recognition of our successes to date, and investment in the future success of V-Smart™ for GBM as a transformative therapeutic for brain cancer patients.”

VABC Chairman Michael Klipper added, “A major goal of VABC is to invest in cutting-edge developments that can have a monumental impact on the course of brain cancer. Certain anti-cancer agents have shown potential, but, because they cannot get into the brain by existing oral or i.v. delivery, fall short for patients.

“This challenge represents a critical unmet need in the field of brain cancer. V-Smart™ for GBM can solve the problem that many potential therapeutic agents for GBM do not cross the BBB.”

About Lauren Sciences LLC

Lauren Sciences LLC is a privately held biotechnology company New York, founded in 2010. The company focuses on using the V-Smart™ drug delivery platform to create a robust pipeline of therapeutics consisting of central nervous system (CNS) active drugs that normally do not cross the blood-brain barrier. Lauren Sciences exclusively licensed the V-Smart™ technology platform and intellectual property estate from BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev.

V-Smart™ Nanomedicines for brain diseases include CNS, neurodegenerative and rare/orphan brain diseases, such as GBM, NPC, ALS, Neuro-AIDS, Parkinson’s, Alzheimer’s, and LSDs, among others, as well as neurodevelopmental and psychiatric disorders. Lauren Sciences has advanced development of its proprietary V-Smart™ pipeline with disease foundations, and has been awarded numerous grants. Lauren Sciences also has strategic partnerships with major pharmaceutical companies, collaborations with prestigious U.S. university medical centers, invitations to present V-Smart™ research at scientific conferences, features in industry research reports, a worldwide patent portfolio, and extensive publications on V-Smart™ in peer-reviewed scientific journals.

About Voices Against Brain Cancer

Voices Against Brain Cancer’s (VABC) mission is to find a cure for brain cancer and brain tumors by advancing scientific research, increasing awareness, creating a brain cancer and tumor community, and supporting patients, their families and caregivers afflicted with this devastating disease. VABC has a wide variety of initiatives in motion for brain cancer research, awareness and support. The organization’s research grants fund cutting-edge programs that will have a monumental impact on the diagnosis and treatment of brain cancer and brain tumors. For more information, visit: www.voicesagainstbraincancer.org.

About American Associates, Ben-Gurion University of the Negev

American Associates, Ben-Gurion University of the Negev (AABGU) plays a vital role in sustaining David Ben-Gurion’s vision: creating a world-class institution of education and research in the Israeli desert, nurturing the Negev community and sharing the University’s expertise locally and around the globe. As Ben-Gurion University of the Negev (BGU) celebrates its 50th birthday this year, AABGU imagines a future that goes beyond the walls of academia. It is a future where BGU invents a new world and inspires a vision for a stronger Israel and its next generation of leaders. Together with supporters, AABGU will help the University foster excellence in teaching, research and outreach to the communities of the Negev for the next 50 years and beyond.

Media Contact:
Andrew Lavin
A. Lavin Communications
516-944-4486
alc@alavin.com